Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs
Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs
复制标题
DOI：
10.1111/j.1365-2036.2005.02560.x
复制
发表时间：
2005-08-01
影响因子：
7.6
通讯作者：
Blatchford, O
中科院分区：
文献类型：
--
作者：
Taha, AS;Angerson, WJ;Blatchford, O
背景：小剂量阿司匹林和其他抗血栓治疗已越来越多地用于血管保护。目的：评估与非甾体类抗炎药相比，使用这些药物的受试者上消化道失血发生率发生变化的可能性。方法：我们研究了 6 年期间在 3 个时间点到同一家医院就诊的所有急性上消化道出血患者的特征：1996 年（n = 204）、1999 年(n = 224) 和 2002 年 (n = 252)。 结果：服用低剂量阿司匹林的受试者中出血发生率从 1996 年的每年每 10 万人口中 15 例上升到 1999 年的 18 例和 2002 年的 27 例（P = 0.004）。服用其他抗血栓药物的受试者的发生率分别为 4、8 和 12（P < 0.001）。在非甾体类抗炎药使用者中没有发现显着变化。然而，急性心肌梗死死亡率1996年为每10万人216人，1999年为221人，2002年降至169人（P<0.001）。结论：小剂量阿司匹林和其他抗血栓药物使用者上消化道出血的发生率一直在稳步上升。与此同时，心脏病死亡率也有所下降。
Background: Low-dose aspirin and other anti-thrombotic therapy has been increasingly used for vascular protection.Aim: To assess the possibility that the incidence of upper gastrointestinal blood loss has changed in subjects using these agents in comparison with non-steroidal anti-inflammatory drugs.Methods: We studied the characteristics of all patients with acute upper gastrointestinal haemorrhage and attending a single hospital at 3 points over a 6-year period: 1996 (n = 204), 1999 (n = 224) and in 2002 (n = 252).Results: The incidence of haemorrhage in subjects taking low-dose aspirin rose from 15 per 100 000 of the population per annum in 1996, to 18 in 1999 and 27 in 2002 (P = 0.004). The respective incidence in subjects taking other anti-thrombotic drugs was 4, 8, and 12 (P < 0.001). No significant change was detected in non-steroidal anti-inflammatory drug users. However, acute myocardial infarction mortality was 216 per 100 000 in 1996, 221 in 1999 and fell to 169 in 2002 (P < 0.001).Conclusions: The incidence of upper gastrointestinal haemorrhage in users of low-dose aspirin and other anti-thrombotic drugs has been steadily rising. This has been paralleled by a fall in cardiac mortality.